Therapy for fungal diseases: opportunities and priorities.
This article provides a perspective on the current status of drug therapy for invasive fungal diseases, together with priorities for the future development of novel compounds. Key opportunities for new drugs include production of orally bioavailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosal and urinary Candida infections. Orally bioavailable agents for the treatment of chronic pulmonary and allergic aspergillosis are also required, as well as new potent drugs against a range of medically important moulds. Antifungal resistance is a problem in certain contexts, but is generally less of a problem than bacterial infections. Earlier and more complete mycological diagnosis and improvements in underlying risk estimation will improve outcomes. The limitations of the current antifungal agents and opportunities for new developments are discussed.
Denning
David W
DW
School of Translational Medicine, Manchester Academic Health Science Centre, University of Manchester, University Hospital of South Manchester, Manchester M23 9LT, UK. ddenning@manchester.ac.uk
Hope
William W
WW
D000935:Antifungal Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D035843:Biomedical Research / Q000639:trends; D055808:Drug Discovery / Q000639:trends*; D025141:Drug Resistance, Fungal; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents